So sad...
Pfizer announces the 'Amaryllis' trial of a PDE-10 inhibitor drug failed to improve symptoms of HD
By Dr Ed Wild on December 16, 2016
Edited by Dr Jeff Carroll
Pfizer has announced that the first-pass analysis of its ‘Amaryllis’ trial, testing a PDE-10 inhibitor drug, shows the drug did not meet its target of improving Huntington’s disease symptoms. As a result, the open-label extension study will be stopped. This is not the news we’d been hoping for, but we’ve learned a lot about HD along the way.
http://en.hdbuzz.net/229
PFE says Amaryllis Trial failed to improve HD
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $7.5K | 1.5M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 56 | 63055651 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 38008482 | 21 |
View Market Depth
| Last trade - 10.00am 12/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |